BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21116782)

  • 1. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells.
    Kim YJ; Lim J; Kang JS; Kim HM; Lee HK; Ryu HS; Kim JY; Hong JT; Kim Y; Han SB
    Arch Pharm Res; 2010 Nov; 33(11):1789-95. PubMed ID: 21116782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model.
    Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB
    Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model.
    Kim HM; Lim J; Kang JS; Park SK; Lee K; Kim JY; Kim YJ; Hong JT; Kim Y; Han SB
    Int Immunopharmacol; 2009 Mar; 9(3):375-80. PubMed ID: 19105981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.
    Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB
    Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
    Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
    Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of cytokine-induced killer cells against human lung cancer.
    Kim HM; Lim J; Park SK; Kang JS; Lee K; Lee CW; Lee KH; Yun MJ; Yang KH; Han G; Kwon SW; Kim Y; Han SB
    Int Immunopharmacol; 2007 Dec; 7(13):1802-7. PubMed ID: 17996691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
    Zhu BQ; Ju SW; Shu YQ
    Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Growth inhibition of human hepatocellular carcinoma xenograft in nude mice by combined treatment with human cytokine-induced killer cells and chemotherapy].
    Shi M; Yao L; Wang FS; Lei ZY; Zhang B; Li WL; Liu JC; Tang ZR; Zhou GD
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):465-8. PubMed ID: 15555334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
    Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
    Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity.
    Doskali M; Tanaka Y; Ohira M; Ishiyama K; Tashiro H; Chayama K; Ohdan H
    J Immunother; 2011 Mar; 34(2):129-38. PubMed ID: 21304407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Induction of dendritic cells from intra-operative lost blood and their effects on CIK against liver cancer cells in vitro].
    DU Z; Zhao XL; Gao YT; Wu CX; Wang YJ; Zhu ZY; Sun Q; Fang SC
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):759-63. PubMed ID: 19173806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells.
    Jiang J; Xu N; Wu C; Deng H; Lu M; Li M; Xu B; Wu J; Wang R; Xu J; Nilsson-Ehle P
    Anticancer Res; 2006; 26(3B):2237-42. PubMed ID: 16821594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
    Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
    Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-15-transferred cytokine-induced killer cells elevated anti-tumor activity in a gastric tumor-bearing nude mice model.
    Peng Z; Liang W; Li Z; Xu Y; Chen L
    Cell Biol Int; 2016 Feb; 40(2):204-13. PubMed ID: 26503216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of in vivo labeled cytotoxic T lymphocytes and cytokine-induced killer cells migration and distribution of subcutaneous gastric tumor model in nude mice].
    Wu ZY; DU XH; Xu YX; Li L; Liu JC; Wang JJ; Li ZX
    Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(6):403-6. PubMed ID: 20367940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers.
    Todorovic M; Mesiano G; Gammaitoni L; Leuci V; Giraudo Diego L; Cammarata C; Jordaney N; Carnevale-Schianca F; Gallo S; Fagioli F; Piacibello W; Elia AR; Pignochino Y; Dell'aglio C; Grignani G; Cignetti A; Aglietta M; Sangiolo D
    J Immunother; 2012 Sep; 35(7):579-86. PubMed ID: 22892454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
    Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
    Lu PH; Negrin RS
    J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.